GlobeNewswire
-
Tris Pharma Introduces New 30-Count Bottle Size for QuilliChew ER® (methylphenidate HCl) Extended-Release Chewable Tablets for Attention Deficit Hyperactivity Disorder (ADHD)
14/09/2026 -
Nord Fascia Launches Personalized Fascia Release and Mobility App
14/09/2026 -
Santa Ana Bio Announces First Subjects Dosed in Phase 1 Study of SAB01 to Treat Autoimmune Inflammatory Diseases
14/09/2026 -
Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy
14/09/2026 -
Alveus Therapeutics Initiates Phase 2 PRESERVE Trial to Evaluate ALV-100 for Chronic Weight Management
14/09/2026 -
Revelyx Bio Reports Positive Topline Phase 2 Results for YY003, a Recombinant, Ready-to-Use Liquid Botulinum Toxin Type A, in Moderate-to-Severe Glabellar Lines
14/09/2026 -
Baird Medical Highlights Participation at CIRSE 2026 and Showcases Microwave Ablation Technology
14/09/2026 -
Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models
14/09/2026 -
Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis
14/09/2026 -
Leios Therapeutics Announces Positive End-of-Phase 2 Meeting with FDA for 10XB-101 for Moderate-to-Severe Submental Fat Fullness
14/09/2026 -
Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting
14/09/2026 -
As New York Fashion Week Kicks Off, Kraig Labs Advances Spider Silk for Fashion's Next Generation of Designers
14/09/2026 -
Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
14/09/2026 -
Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
14/09/2026 -
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma
14/09/2026 -
Slate Medicines Appoints Kenneth Koblan, PhD, as Chief Scientific Officer
14/09/2026 -
GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)
14/09/2026 -
Soleo Health Expands Atlanta Footprint With Infusion Centers In Woodstock and Fayetteville, Georgia
14/09/2026 -
Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference
14/09/2026
Pages